TMCnet News
Shortage of Heart Donors Will Drive the Global Ventricular Assist Devices Market in the Coming Years: TechNavioTechNavio has announced the publication of a new market research report on the Global Ventricular Assist Devices (VADs) Market, which is expected to grow at a CAGR of 12.04 percent from 2014-2019. About the Report The latest report by TechNavio emphasizes the unavailability of heart donors in the market. Heart transplantation is the only effective treatment for people with severe heart failure, but finding a heart donor has become difficult. "In the US, the average waiting time for a donor heart is about 9-11 months, however many patients have to wait for as long as two years. This has increased the adoption of ventricular assist devices," says Faisal Ghaus, Vice President of TechNavio. The report also highlights the increased use of ventricular assist devices for bridge to transplant (BTT) therapy. VADs can help patients on the transplant waiting list gain strength, and increases their chance of survival until a suitable donor is found. "Certain approved VADs for BTT therapy are available in the market like HeartMate II LVAS, Thoratec PVAD and LVAD, which are FDA approved," says Ghaus. Additionally, clinical trials have also been initiated by vendors for their pipeline products. Players like Thoratec have recently begun enrolling patients in its HeartMate III US clinical trial. Key Information Covered in the Report:
If you are interested in more information, please contact our media team at [email protected]. |
